Abstract Hypomethylating agents (HMA) have become the backbone of nonintensive acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) treatment, also by virtue their activity in patients with adverse genetics, for example, monosomal karyotypes, often losses on chromosome 7, 5, or 17. No comparable is observed cytarabine, a cytidine analogue without DNA-hypomethylating properties. As evidence...